708. In Vitro Activity of Plazomicin vs. Clinical Isolates of Gram-Negative Bacilli, Including Aminoglycoside Nonsusceptible and Multidrug-Resistant Subsets, Recovered from Patients Across Canada as Part of the CANWARD study, 2011–2018

BACKGROUND: Plazomicin (PLZ) is a next-generation aminoglycoside currently approved by the US FDA for the treatment of complicated urinary tract infections, including pyelonephritis. The purpose of this study was to evaluate the in vitro activity of PLZ against a large collection of Gram-negative ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Walkty, Andrew, Adam, Heather, Baxter, Melanie, Lagace-Wiens, Philippe, Karlowsky, James, Zhanel, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810879/
http://dx.doi.org/10.1093/ofid/ofz360.776

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810879/
http://dx.doi.org/10.1093/ofid/ofz360.776

Ejemplares similares